Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA Dose Response for Upper Facial Wrinkles
NCT04994990Withdrawn
- Sponsor
- Northwell Health
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised trial of botulinum toxin type A in rhytides (2 arms), sponsored by Northwell Health. Primary endpoints: Upper Face Wrinkle Severity at 4 months and Patient Satisfaction at 4 months. Planned start May 2023; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
rhytides
Beyond the preview
Go deeper on NCT04994990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994990.